Osimertinib received its initial FDA approval on November 3, 2015, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) whose disease had progressed on or after a prior EGFR tyrosine kinase inhibitor (TKI) therapy [1]. This approval was granted under the FDA's priority review designation [1].
When Did Osimertinib Get Approved for First-Line Treatment?
Osimertinib's indication was later expanded to include first-line treatment. On April 18, 2018, the FDA approved osimertinib for patients with metastatic EGFR T790M mutation-positive NSCLC who had not received prior TKI therapy [2]. This expanded approval was also based on its effectiveness in patients with central nervous system (CNS) metastases [2].
What is the FDA Approval Status for Other EGFR Mutations?
The FDA's approvals for osimertinib are specifically tied to the presence of the EGFR T790M mutation. It is indicated for patients with either the T790M mutation or activating EGFR mutations (such as exon 19 deletions or L858R substitutions) in the first-line setting [2].
What is the History of Osimertinib's Clinical Trials?
The initial FDA approval in 2015 was based on data from two single-arm, open-label trials, including the AURA extension study and the AURA2 study [1]. The subsequent first-line approval in 2018 was supported by findings from the Phase III FLAURA trial, which demonstrated superior progression-free survival (PFS) compared to other EGFR TKIs in the first-line setting [2].
What is the Current Regulatory Status and Potential Exclusivity?
Information on the specific patent expiry dates and any ongoing patent challenges for osimertinib can be found through resources like DrugPatentWatch.com [3]. These details are crucial for understanding when generic or biosimilar versions of the drug might become available.